Biotechnology News 30 December 2025

Regencell Bioscience (RGC) stock slid 8% into the New Year’s Day market shutdown — what’s next

NEW YORK, January 1, 2026, 10:46 ET — Market closed. Regencell Bioscience Holdings’ shares last closed down 8.3% at $21 on Wednesday, just before U.S. markets shut for the New Year’s Day holiday. New York Stock Exchange The latest swing

1 January 2026

Biotechnology·Financial News·Investing·Market Analysis·Stock Market

Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

NEW YORK, January 1, 2026, 07:56 ET — Market closed Cytokinetics, Incorporated (CYTK.O) shares rose $2.17, or 3.5%, to $63.54 in the last trading session of 2025, after swinging between $60.93 and $64.43 on volume of about 1.85 million shares.

1 January 2026

Biotechnology·Investment Analysis·Pharmaceuticals·Stock Market

Axsome (AXSM) stock jumps after FDA sets April decision date for Alzheimer’s agitation filing

NEW YORK, January 1, 2026, 07:18 ET — Market closed Key points: With U.S. markets closed on Thursday for the New Year’s Day holiday, Axsome Therapeutics shares were last up 22.9% at $182.64 after the company said the FDA granted

1 January 2026

Biotechnology·FDA News·Investment Updates·Stock Market

Axsome stock jumps 23% after FDA sets April 30 deadline for Alzheimer’s agitation review

NEW YORK, January 1, 2026, 03:20 ET — Market closed Axsome Therapeutics Inc shares jumped 22.9% to $182.64 in Wednesday’s session, after touching $184.40, with about 3.1 million shares traded. The CNS drugmaker said the U.S. Food and Drug Administration

1 January 2026

Biotechnology·FDA News·Stock Market

INBS stock whipsaws after Intelligent Bio Solutions lines up $10 million funding

NEW YORK, January 1, 2026, 03:10 ET — Market closed Intelligent Bio Solutions Inc said late Wednesday it will raise about $10 million in a private placement, sending its shares lower in after-hours trading after a sharp rally earlier in

1 January 2026

Biotechnology·Financial Updates·Investment·Stock Market

BillionToOne (BLLN) stock slides 4% in thin year-end trade as investors look to January catalysts

NEW YORK, December 31, 2025, 15:27 ET — Regular session. Shares of BillionToOne (BLLN.O) fell about 4% on Wednesday, sliding $3.49 to $81.61 in afternoon trading. The stock has traded between $81.25 and $89.36, with about 243,000 shares changing hands.

31 December 2025

Biotechnology·Financial News·Investing·Market Trends·Stock Market

Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing

NEW YORK, December 31, 2025, 14:52 ET — Regular session Cytokinetics, Incorporated shares rose 3.7% to $63.63 in afternoon trading on Wednesday, after touching $64.40 earlier in the session. The stock traded as low as $60.87, while the S&P 500

31 December 2025

Biotechnology·Company Analysis·Investment Trends·Pharma News·Stock Market

Axsome Therapeutics (AXSM) stock jumps 23% after FDA priority review for Alzheimer’s agitation filing

NEW YORK, December 31, 2025, 14:41 ET — Regular session Axsome Therapeutics shares jumped 23% in afternoon trading on Wednesday after the company said U.S. regulators accepted its application and granted a faster review for AXS-05 to treat agitation in

31 December 2025

Biotechnology·FDA News·Investment·Pharmaceuticals·Stock Market

INBS stock surges 160% as Intelligent Bio Solutions strikes manufacturing deal targeting 40% cost cuts

NEW YORK, December 31, 2025, 13:04 ET — Regular session Intelligent Bio Solutions Inc shares surged on Wednesday after the company said it struck a new manufacturing partnership aimed at lowering costs for its fingerprint-based drug testing device. The stock

31 December 2025

Biotechnology·Business News·Investments·Stock Market

Cogent Biosciences (COGT) stock slips as insider sales follow bezuclastinib FDA filing

NEW YORK, December 31, 2025, 11:55 ET — Regular session Shares of Cogent Biosciences slid on Wednesday, paring losses from earlier in the session, after the biotech disclosed a key regulatory filing while investors digested a cluster of insider stock

31 December 2025

Biotechnology·FDA Approvals·Insider Trading·Pharma News·Stock Market

GRAIL stock drops in New York session as Galleri FDA filing timeline returns to focus

NEW YORK, December 30, 2025, 15:32 ET — Regular session GRAIL Inc shares were down 3.3% at $84.95 in afternoon trading on Tuesday, after earlier touching $84.77. The early-cancer detection company is trying to turn Galleri — a multi-cancer early

30 December 2025

Biotechnology·Investment News·Stock Market

Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

NEW YORK, December 30, 2025, 14:30 ET — Regular session Shares of Kymera Therapeutics fell about 3% to $77.94 in afternoon trading on Tuesday, lagging a broader biotech dip. The SPDR S&P Biotech ETF was down about 1.4%, while the

30 December 2025

Biotechnology·Financial News·Investing·Stock Market·Trading Strategies

Biotechnology News 30 December 2025 - 1 January 2026